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ABSTRACT:
Aim of study. Mechanical thrombectomy (MT) is one of the aetiological treatment options recommended for anticoagulated 
patients with acute ischaemic stroke (AIS). We analysed its long-term outcomes using the modified Rankin Score (mRS) or 
mortality on day 90.
Clinical rationale for the study. Data describing the anticoagulant efficacy and safety of MT in patients with AIS is limited.
Materials and methods. This study included 291 patients with AIS (49% women, mean [SD] age 66 [15] years) who underwent 
MT in the Comprehensive Stroke Centre in Krakow, Poland. Data describing demographics, stroke risk factors, NIHSS on admis-
sion, postprocedural thrombolysis in cerebral infarction score, 24-hour postprocedural haemorrhagic transformation (ECASS-2) 
as seen on computed tomography, and time between stroke onset and groin puncture was collected. The outcome measure 
was the mRS on day 90 after stroke onset (a favourable outcome was defined as an mRS not exceeding 2 points; an unfavourable 
outcome was death). 
Results. Thirty-seven patients (13%) were on therapeutic anticoagulation during MT. Univariate analysis showed that anticoagu-
lated patients were older and more likely to have been diagnosed with hypertension, ischaemic heart disease, or atrial fibrillation. 
The patient groups did not differ in terms of clot location, postprocedural thrombolysis in cerebral infarction score, haemorrhagic 
transformation on computed tomography, or mRS on day 90. Multivariate logistic regression analysis showed that younger age, 
male sex, no history of diabetes mellitus, lower NIHSS score on admission, shorter time between stroke onset and groin puncture, 
and better recanalisation were associated with favourable outcomes at day 90, and that therapeutic anticoagulation was not (OR, 
1.00; 95%CI, 0.46-2.15; p = 0.99). Anticoagulation did not affect mortality at day 90 (OR, 1.28; 95%CI, 0.56-2.92; p = 0.55).
Conclusion and clinical implications. In anticoagulated patients with AIS, MT does not affect long-term outcomes. 
Key words: mechanical thrombectomy, acute ischaemic stroke, novel oral anticoagulants, anticoagulation, atrial fibrillation
(Neurol Neurochir Pol 2020; 54 (6): 538–543)
Introduction
Atrial fibrillation (AF) substantially contributes to stroke 
risk [1]. Both vitamin K antagonists (VKAs) and novel oral 
anticoagulants (NOACs) significantly decrease this risk.
However, 1.11–3.24% of patients with AF develop stroke 
despite anticoagulant treatment [2]. 
A couple of aetiological treatment options are recom-
mended for anticoagulated patients who have developed acute 
ischaemic stroke (AIS): 
1. an intravenous tissue plasminogen activator when treat-
ment includes a VKA, and the international normalised 
ratio (INR) is less than or equal to 1.7, or when treatment 
includes a NOAC and laboratory tests show that the 
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anticoagulatory effect of NOACs is probably absent or 
when the last dose of the NOAC was more than 48 hours 
previously, or 
2. mechanical thrombectomy (MT) when the patient fulfills 
all commonly accepted treatment guidelines [3, 4].
Clinical rationale for study
Data describing the efficacy and safety of MT for AIS in 
patients using oral anticoagulants is limited.
Materials and methods
Experimental procedure
This retrospective analysis was performed on prospectively 
collected data from the Krakow Stroke Data Bank, a single-cen-
tre, hospital-based registry of clinical radiological and genetic 
data from patients with AIS, systematically collected since 2007. 
This study design was approved by the Jagiellonian University 
Ethical Committee (KBET 54/B/2007). The analysis included 
data from 291 patients with AIS treated with MT between Janu-
ary 2013 and April 2019. Detailed patient work-ups are described 
elsewhere [5]. Participants were categorised as either those given 
therapeutic anticoagulation or those not anticoagulated before 
stroke. The former were treated with full doses of oral antico-
agulants (i.e. VKAs, NOACs, or low-molecular-weight heparin 
[LMWH]) with or without haemostasis disturbances detected via 
laboratory tests at admission. Contemporaneous anticoagulant 
treatment information was collected from medical histories and 
information from the patients or relatives. The latter were those 
with medical histories or relatives not describing anticoagulant 
treatments and without haemostasis disturbances detected via 
laboratory tests at admission. The outcome measure was mRS 
on day 90 after stroke onset. A favourable outcome was defined 
as an mRS not exceeding 2 points. 
Statistical methods
Clinical characteristics and outcomes were compared 
using the unpaired t test or the chi-square test, as appropri-
ate. To identify potential independent outcome predictors, 
variables showing p-values < 0.05 in univariate analyses were 
subsequently included in a multivariate regression analysis. 
Because this study was focused on analysing the significance of 
therapeutic anticoagulation on long-term outcome measures, 
two models for each outcome were used: one with, and one 
without, therapeutic anticoagulation.
All statistical analyses were performed using Statistica 
software (version 12.5, Statsoft, Poland) When p < 0.05, sta-
tistical significance was recognised.
Results
The group receiving anticoagulant therapy comprised 
37 patients (13%). Of these, 14 were treated with VKAs, four 
with LMWH, and 19 with NOACs (six with dabigatran, and 
13 with rivaroxaban). Therapeutic anticoagulation was used 
to treat atrial fibrillation in 30 patients and venous thrombo-
embolism in seven patients. Compared to those not receiving 
anticoagulants, these patients were older and more likely to 
have ischaemic heart disease or AF (Tab. 1). Clot locations were 
similar in both groups, as were postprocedural thrombolysis 
in cerebral infarction (TICI) scores, 24-hour postprocedural 
haemorrhagic transformations based on computed tomogra-
phy (CT) according to ECASS-2 [6], and mRS distributions 
at day 90 (Tab. 1). Cardioembolic stroke was more common 
in anticoagulated patients, but large vessel disease stroke, 
stroke of unknown cause, and stroke of rare aetiology were 
not (Tab. 1).
Favourable outcomes were found at day 90 for 154 patients 
(52.9%); 63 (21.6%) died. Results of univariate analyses com-
paring patients with favourable to those with unfavourable 
outcomes, and comparing survivors to non-survivors at day 
90, are set out in Table 2.
Multivariate logistic regression analysis showed that 
younger age, male sex, no history of diabetes mellitus, lower 
NIHSS score on admission, better recanalisation as measured 
by TICI score (2b or 3), and shorter time from stroke onset to 
groin puncture were associated with favourable outcomes (an 
mRS not exceeding 2 at day 90). Therapeutic anticoagulation 
did not affect outcome (Tab. 3). In one multivariate logistic 
regression model, older age and poor recanalisation (TICI 
scores of 0, 1, or 2a), but not therapeutic anticoagulation, 
were significantly correlated with mortality at day 90 (Tab. 3).
Discussion
The number of AIS patients treated by means of IVT or MT 
has increased significantly in recent years [7–9]. As shown in 
other studies [10–16], we found that MT used to treat AIS in 
anticoagulated patients did not change long-term outcomes 
compared to non-coagulated AIS patients treated by MT. Age, 
sex, time from stroke onset to groin puncture, neurological 
deficit as measured by the NIHSS, rate of recanalisation as 
assessed using the TICI score, and diabetes mellitus were 
confirmed as correlating with outcome.
However, it should be noted that outcome based on mRS 
on day 90 was defined differently in other studies. An excel-
lent outcome has been described as an mRS of 0 or 1 [17], 
a favourable outcome has been described as an mRS of 0, 1, 
or 2 [10–12,14,17], and an unfavourable outcome has been 
defined as an mRS of 3–6, 4–6, or 6 [10, 13–16, 18]. Of nine 
published studies, five, including this one [10, 13, 14], evalu-
ated at least two outcome measures based on mRS.
It is well known that MT is included in the guidelines for 
treating AIS [3, 4], and that today it is the most effective treat-
ment related to good outcomes. The number of points needed 
to treat is 3 to achieve an mRS of 0, 1, or 2 on day 90 [19]. It 
should be noted, however, that most studies on this topic show 
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Table 1. Demographics, clinical characteristics and outcomes in patients under therapeutic anticoagulation and in patients not anticoagulated at time of 
mechanical thrombectomy (univariate analysis)
Parameter
Anticoagulated  
patients (n = 37)
Non-anticoagulated 
patients (n = 254)
p
Demographics
Age, years (mean ± SD) 71.8 (± 8.5) 65.8 (± 14.9) 0.0001
Female (n, %) 18 (48.6) 125 (49.2) 0.95
Stroke risk factors
Hypertension (n, %) 33 (89.2) 176 (69.5) 0.012
Ischaemic heart disease (n, %) 19 (51.4) 70 (27.7) 0.0033
Atrial fibrillation (n, %) 30 (81.0) 64 (25.4) < 0.00001
Diabetes mellitus (n, %) 10 (27.0) 86 (34.0) 0.41
Clinical parameters
Time from stroke onset to groin puncture (hours) (mean ± SD) 4.07 ± 1.39 4.53 ± 1.17 0,13
NIHSS on admission (mean ± SD) 14.2 ± 6.0 15.7 ± 6.2 0.19
Clot location
MCA, M1 (n, %) 17 (45.9) 123 (48.4) 0.78
MCA, M2 (n, %) 6 (16.2) 43 (16.9) 0.91
MCA, M3 (n, %) 1 (2.7) 6 (2.3) 0.90
M1+M2 (n, %) 0 (0.0) 2 (1.0) N/A
ICA (n, %) 6 (16.2) 43 (16.9) 0.91
ICA + MCA, M1 (n, %) 4 (10.8) 12 (4.7) 0.13
A1 (n, %) 0 (0.0) 0 (0.0) N/A
BCA and/or VA (n, %) 2 (5.3) 21 (8.3) 0.55
Multiple locations (n, %) 1 (2.7) 3 (1.2) 0.46
TICI score post-thrombectomy
TICI 0 (n, %) 3 (8.1) 19 (7.5) 0.86
TICI 1 (n, %) 3 (8.1) 12 (4.7)
TICI 2a (n, %) 5 (13.5) 36 (14.2)
TICI 2b (n, %) 7 (18.9) 64 (25.2)
TICI 3 (n, %) 19 (51.4) 123 (48.4)
Haemorrhagic transformation (ECASS-2)
No haemorrhage (n, %) 19 (51.4) 147 (57.9) 0.16
HI-1 (n, %) 16 (43.2) 70 (27.6)
HI-2 (n, %) 0 (0.0) 1 (0.4)
PH-1 (n, %) 1 (2.7) 15 (5.9)
PH-2 (n, %) 1 (2.7) 21 (8.3)
Stroke aetiology
Large vessel disease (n, %) 2 (5.4) 29 (11.5) < 0.05
Small vessel disease (n, %) 0 (0.0) 0 (0.0)
Cardiac-embolic stroke (n, %) 31 (83.8) 104 (41.3)
Unknown cause (n, %) 3 (8.1) 72 (28.2)
Rare cause (n, %) 1 (2.7) 50 (19.8)
Stroke outcome (modified Rankin Score on day 90)
mRS: 0 14 (37.9) 87 (34.3) 0.89
mRS: 1 2 (5.4) 34 (13.4)
mRS: 2 3 (8.1) 14 (5.5)
mRS: 3 2 (5.4) 23 (9.1)
mRS: 4 3 (8.1) 20 (7.9)
mRS: 5 3 (8.1) 23 (9.0)
mRS: 6 10 (27.0) 53 (20.8)
BCA — basal cerebral artery; ECASS-2 classification: HI-1: small petechiae, HI-2: more confluent petechiae, PH-1: < 30% of the infarcted area with mild space-occupying effect, PH-2 > 30% of the infarcted area with 
significant space-occupying effect; ICA — internal carotid artery; MCA — middle cerebral artery, MCA M1— sphenoidal or horizontal segment; MCA M2 — insular segment; MCA M3 — opercular segment; N/A — not 
applicable; NS — not significant; SD — standard deviation; TICI — Thrombolysis in Cerebral Infarction: TICI 0 — no perfusion; TICI 1 — penetration with minimal perfusion; TICI 2a — only partial filling (less than two-
-thirds) of the entire vascular territory is visualised; TICI 2b — complete filling of all of the expected vascular territory is visualised but filling is slower than normal; TICI 3 — complete perfusion; VA — vertebral arteries
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Table 2. Demographics and stroke characteristics in patients treated by mechanical thrombectomy with mRS: 0–2 vs. mRS: 3–6 and mRS: 0–5 vs. mRS: 6 at 
day 90 after stroke (univariate analysis)
Parameter
mRS: 0–2 mRS: 3–6 p mRS: 0–5 mRS: 6 p
N = 154 N = 137 N = 228 N = 63
Demographics
Age (years), mean ± SD 62.9 ± 14.7 70.7 ± 12.9 0.000002 65.4 ± 14.7 71.1 ± 12.4 0.0051
Gender (females), n (%) 61 (39.6) 82 (59.9) 0.00057 108 (47.4) 35 (55.6) 0.25
Stroke risk factors
Hypertension, n (%) 106 (68.8) 103 (75.2) 0.39 158 (69.3) 51 (81) 0.069
Diabetes mellitus, n (%) 30 (19.5) 50 (36.5) 0.0012 58 (25.4) 22 (34.9) 0.14
Ischaemic heart disease, n (%) 42 (27.3) 41 (29.9) 0.62 60 (26.3) 23 (36.5) 0.11
Atrial fibrillation, n (%) 55 (35.7) 61 (44.5) 0.13 87 (38.2) 29 (46) 0.26
Clinical parameters
Poor recanalisation TICI, n (%)   0–2a 20 (13.0) 58 (42.3) < 0.00001 52 (22.4) 27 (42.9) 0.0012
Time from stroke onset to groin puncture (hours), mean ± 
SD
4.3 ± 1.7 4.7 ± 1.8 0.02 4.4 ± 1.81 4.54 ± 1.44 0.75
NIHSS on admission, mean ± SD 14.5 ± 6.5 16.6 ± 5.6 0.0027 15.1 ± 6.1 16.9 ± 6.4 0.04
Treatment
Therapeutic anticoagulation during acute ischaemic stroke 19 (12.3) 18 (13.2) 0.84 27 (11.8) 10 (15.8) 0.4
mRS — modified Rankin Scale; NIHSS — National Institutes of Health Stroke Scale; TICI — thrombolysis in cerebral infarction 
that MT does not decrease mortality [20]. Additional studies 
should focus on the various aspects of MT prognoses and on 
two general outcome measures: favourable and unfavourable.
The number of published studies analysing the significance 
of MT in anticoagulated patients with stroke is increasing. 
Taken together, 1,013 anticoagulated patients treated with 
MT have been studied, and of those 176 (17.4%) were given 
NOACs. An analysis of 28 patients with AIS who were enrolled 
in the Registry of Acute Ischaemic Stroke Under New Oral 
Anticoagulants, anticoagulated with NOACs, and treated using 
MT was performed by Purrucker et al. [10] without a control 
group. Separately, Seiffge et al. [16] used a propensity score 
matching method to compare three cohorts of acute stroke 
patients: 78 anticoagulated with NOACs, 441 with VKAs, and 
8,938 not anticoagulated. 
In neither study were NOACs found to have a negative 
influence on the safety and outcomes of acute stroke treated 
by MT.
 To determine whether anticoagulation in patients with 
AIS treated by MT was significant, several national and 
international registries have been recently announced: the 
RASUNOA-prime (Rationale and design of the Registry of 
Acute Stroke Under Novel Oral Anticoagulants-prime) registry 
[21], the ENDOSTROKE registry [12], and the Registry of 
Acute Ischaemic Stroke Under New Oral Anticoagulants [10].
Our study also showed that MT in anticoagulated pa-
tients did not increase the risk of intracranial haemorrhage 
as observed on CT scans performed within 24 hours of the 
procedure. All studies, including this one, show similar 
distributions of brain haemorrhage severity according 
to ECASS-II in anticoagulated and non-anticoagulated 
patients [10–16, 17, 18].
 In our study, all patients with AIS who were current users 
of anticoagulants were treated with MT without prior intra-
venous thrombolysis. Of four patients receiving full doses of 
LMWH, two had prolonged APTTs. Similarly, of 14 receiving 
VKAs, eight had prolonged INRs. Of six patients receiving 
dabigatran, two had prolonged APTTs, and 11/13 taking 
rivaroxaban had prolonged PTs. 23 patients or relatives were 
unable to indicate when the last dose of anticoagulant had 
been administered.
Currently, specific coagulation tests analysing NOAC 
concentrations are not commonly available. The test that is 
typically used requires an hour to yield results, hampering 
treatment decisions about anticoagulation in acute stroke 
patients. Because about 10% of acute stroke patients admitted 
to a stroke unit are anticoagulated, bedside tests delivering 
immediate results on anticoagulation status are needed.
This study has several limitations. Firstly, its small sample 
size can lead to type II errors. Secondly, it carries all limitations 
inherent in retrospective analyses of prospectively collected 
data. Thirdly, because the numbers of patients receiving each 
specific anticoagulant were small, we were unable to compare 
patient groups.
Clinical implications and future directions
This study confirms the results of others [22, 23], namely 
that MT is safe and efficacious in anticoagulated patients 
with AIS. 
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Table 3. Multivariate regression models analysing factors affecting favourable outcome (mRS = 0–2) or death (mRS = 6) at day 90 including and excluding 
therapeutic anticoagulation
Factors affecting favourable outcome at day 90 (mRS:0-2)
OR 95% CI P
Demographics
Age (years) 0.95 0.93–0.98 0.000081
Gender (female) 0.57 0.32–0.998 0.048
Stroke risk factors
Diabetes mellitus 0.42 0.22–0.77 0.0053
Clinical parameters
NIHSS on admission 0.95 0.91–0.99 0.031
Poor recanalisation (TICI post-thrombectomy: 0, 1, 2a) 0.15 0.08–0.30 0.000000029
Time from stroke onset to groin puncture, hours 0.74 0.62–0.88 0.00051
Factors affecting favourable outcome at day 90 (mRS:0-2), model including therapeutic anticoagulation
Demographics
Age (years) 0.96 0.93–0.98 0.000093
Gender (female) 0.57 0.32–0.999 0.049
Stroke risk factors
Diabetes mellitus 0.42 0.22–0.77 0.0053
Clinical parameters
 NIHSS on admission 0.95 0.91–0.99 0.032
Poor recanalisation (TICI post-thrombectomy: 0, 1, 2a) 0.15 0.08–0.30 0.000000029
Time from stroke onset to groin puncture 0.74 0.62–0.88 0.00053
Treatment
Therapeutic anticoagulation 1.00 0.46–2.15 0.99
Factor affecting risk of death at day 90
Demographics
Age (years) 1.03 1.008–1.06 0.0077
Gender (female) 0.97 0.52–1.81 0.91
Clinical parameters
Poor recanalisation (TICI post-thrombectomy: 0, 1, 2a) 2.69 1.46–4.95 0.0014
NIHSS 1.04 0.99–1.10 0.094
Factors affecting risk of death at day 90, model including therapeutic anticoagulation
Demographics
Age (years) 1.03 1.01–1.06 0.0099
Gender (female) 0.98 0.52–1.83 0.95
Clinical parameters
Poor recanalisation (TICI post-thrombectomy: 0, 1, 2a) 2.68 1.45–4.93 0.0015
NIHSS 1.04 0.99–1.10 0.086
Treatment
Therapeutic anticoagulation 1.28 0.56–2.92 0.55
mRS — modified Rankin Scale; NIHSS — National Institutes of Health Stroke Scale; TICI — thrombolysis in cerebral infarction
 However, systematic studies that include data on coagula-
tion status and the decision-making procedure before MT, and 
comparing the various anticoagulation drugs in the context of 
acute stroke treatment, are necessary.
Acknowledgements: We received no grant from any funding 
agency in the public, commercial, or not-for-profit sector to 
support this research.
Disclosures: The authors declare no conflict of interest.
543www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Klaudia Nowak et al., Mechanical thrombectomy for acute ischaemic stroke during therapeutic anticoagulation
References:
1. Freedman B, Porpara TS, Lip GY. Stroke prevention in atrial fibrillation. 
Lancet. 2016; 388: 806–17.
2. Alberts M, Eikelboom J, Hankey G. Antithrombotic therapy for stroke 
prevention in non-valvular atrial fibrillation. The Lancet Neurology. 
2012; 11(12): 1066–1081, doi: 10.1016/s1474-4422(12)70258-2.
3. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the 
Early Management of Patients With Acute Ischemic Stroke: A Guide-
line for Healthcare Professionals From the American Heart Associa-
tion/American Stroke Association. Journal of Vascular Surgery. 2018; 
67(6): 1934, doi: 10.1016/j.jvs.2018.04.007.
4. Correction to: Guidelines for the Early Management of Patients With 
Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the 
Early Management of Acute Ischemic Stroke: A Guideline for Health-
care Professionals From the American Heart Association/American 
Stroke Association. Stroke. 2019; 50(12): e440–e441, doi: 10.1161/
STR.0000000000000215, indexed in Pubmed: 31765293.
5. Nowak K, Derbisz J, Jagiełła J, et al. Time from stroke onset to gro-
in puncture affects rate of recanalisation after mechanical throm-
bectomy: a real-life single centre experience. Neurol Neurochir Pol. 
2020; 54(2): 156–160, doi: 10.5603/PJNNS.a2020.0024, indexed 
in Pubmed: 32242914.
6. Yaghi S, Willey JZ, Cucchiara B, et al. American Heart Association Stro-
ke Council; Council on Cardiovascular and Stroke Nursing; Council on 
Clinical Cardiology; and Council on Quality of Care and Outcomes Re-
search. Treatment and Outcome of Hemorrhagic Transformation After 
Intravenous Alteplase in Acute Ischemic Stroke: A Scientific Statement 
for Healthcare Professionals From the American Heart Association/
American Stroke Association. Stroke. 2017; 48(12): e343–e361, doi: 
10.1161/STR.0000000000000152, indexed in Pubmed: 29097489.
7. Lattanzi S, Silvestrini M. Future challenges of stroke treatment. 
Neurol Neurochir Pol. 2018; 52(3): 415–416, doi: 10.1016/j.
pjnns.2018.02.004, indexed in Pubmed: 29486885.
8. Łabuz-Roszak B, Starostka-Tatar A, Lasek-Bal A, et al. Diagnostics, 
treatment and secondary prevention of ischemic stroke in the Silesian 
Province, Poland between 2009 and 2015. Neurol Neurochir Pol. 
2018; 52(2): 235–242, doi: 10.1016/j.pjnns.2017.11.003, indexed 
in Pubmed: 29198761.
9. Wiącek M, Kaczorowski R, Sieczkowski B, et al. Mechanical throm-
bectomy: Determining the proportion of eligible acute ischemic stroke 
patients in the cohort of single academic stroke center. Neurol Neuro-
chir Pol. 2018; 52(3): 359–363, doi: 10.1016/j.pjnns.2017.12.010, 
indexed in Pubmed: 29331206.
10. Purrucker JC, Wolf M, Haas K, et al. Safety of Endovascular Throm-
bectomy in Patients Receiving Non-Vitamin K Antagonist Oral Anti-
coagulants. Stroke. 2016; 47(4): 1127–1130, doi: 10.1161/STRO-
KEAHA.116.012684, indexed in Pubmed: 26931156.
11. Zapata-Wainberg G, Ximénez-Carrillo Á, Trillo S, et al. Madrid Stroke 
Network. Mechanical thrombectomy in orally anticoagulated patients 
with acute ischemic stroke. J Neurointerv Surg. 2018; 10(9): 834–
838, doi: 10.1136/neurintsurg-2017-013504, indexed in Pubmed: 
29275325.
12. Uphaus T, Singer OC, Berkefeld J, et al. Safety of endovascular treat-
ment in acute stroke patients taking oral anticoagulants. Int J Stroke. 
2017; 12(4): 412–415, doi: 10.1177/1747493016677986, indexed 
in Pubmed: 28353412.
13. De Marchis GM, Jung S, Colucci G, et al. Intracranial hemorrhage, 
outcome, and mortality after intra-arterial therapy for acute ischemic 
stroke in patients under oral anticoagulants. Stroke. 2011; 42(11): 
3061–3066, doi: 10.1161/STROKEAHA.111.615476, indexed in 
Pubmed: 21980194.
14. Benavente L, Larrosa D, García-Cabo C, et al. Safety and Efficacy of 
Mechanical Thrombectomy in Acute Ischemic Stroke of Anticoagu-
lated Patients-A Prospective Observational Study. J Stroke Cerebro-
vasc Dis. 2016; 25(9): 2093–2098, doi: 10.1016/j.jstrokecerebro-
vasdis.2016.06.006, indexed in Pubmed: 27378732.
15. Rebello LC, Haussen DC, Belagaje S, et al. Endovascular Treatment 
for Acute Ischemic Stroke in the Setting of Anticoagulation. Stroke. 
2015; 46(12): 3536–3539, doi: 10.1161/STROKEAHA.115.011285, 
indexed in Pubmed: 26470775.
16. Seiffge DJ, Hooff RJ, Nolte CH, et al. NOACISP Study Group*. Recana-
lization therapies in acute ischemic stroke patients: impact of prior 
treatment with novel oral anticoagulants on bleeding complications 
and outcome. Circulation. 2015; 132(13): 1261–1269, doi: 10.1161/
CIRCULATIONAHA.115.015484, indexed in Pubmed: 26232277.
17. Wong JWP, Churilov L, Dowling R, et al. Safety of Endovascular 
Thrombectomy for Acute Ischaemic Stroke in Anticoagulated Pa-
tients Ineligible for Intravenous Thrombolysis. Cerebrovasc Dis. 2018; 
46(5-6): 193–199, doi: 10.1159/000493801, indexed in Pubmed: 
30384367.
18. Kurowski D, Jonczak K, Shah Q, et al. Safety of Endovascular Interven-
tion for Stroke on Therapeutic Anticoagulation: Multicenter Cohort 
Study and Meta-Analysis. J Stroke Cerebrovasc Dis. 2017; 26(5): 
1104–1109, doi: 10.1016/j.jstrokecerebrovasdis.2016.12.027, in-
dexed in Pubmed: 28110890.
19. Endovascular Therapy for Ischemic Stroke. New England Journal of 
Medicine. 2015; 372(24): 2363–2366, doi: 10.1056/nejmc1504715.
20. Campbell BCV, Mitchell PJ, Kleinig TJ, et al. EXTEND-IA Investigators. 
Endovascular therapy for ischemic stroke with perfusion-imaging se-
lection. N Engl J Med. 2015; 372(11): 1009–1018, doi: 10.1056/
NEJMoa1414792, indexed in Pubmed: 25671797.
21. Haas K, Purrucker JC, Rizos T, et al. Rationale and design of the 
Registry of Acute Stroke Under Novel Oral Anticoagulants-pri-
me (RASUNOA-prime). Eur Stroke J. 2019; 4(2): 181–188, doi: 
10.1177/2396987318812644, indexed in Pubmed: 31259266.
22. Meinel TR, Frey S, Arnold M, et al. Clinical presentation, diagnostic 
findings and management of cerebral ischemic events in patients on 
treatment with non-vitamin K antagonist oral anticoagulants - A sy-
stematic review. PLoS One. 2019; 14(3): e0213379, doi: 10.1371/
journal.pone.0213379, indexed in Pubmed: 30925155.
23. Liu M, Zheng Y, Li G. Safety of Recanalization Therapy in Patients with 
Acute Ischemic Stroke Under Anticoagulation: A Systematic Review 
and Meta-Analysis. J Stroke Cerebrovasc Dis. 2018; 27(9): 2296–
2305, doi: 10.1016/j.jstrokecerebrovasdis.2018.04.012, indexed in 
Pubmed: 30017747.
